Evotec subsidiary moves JST-018 orthopoxvirus antibodies into Phase 1
First-in-human Phase 1 study has started for investigational orthopoxvirus antibodies developed under the U.S. Department of War Accelerated Antibodies Program, supporting biodefense countermeasures.